EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Nanobody‐based heavy chain antibodies and chimeric antibodies

Friedrich Koch-Nolte iD

Immunological Reviews · 2024

DOI: 10.1111/imr.13385 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Friedrich Koch-Nolte. Beteiligte Einrichtung: Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Immunoglobulin Heavy Chains, Single-Domain Antibodies. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Wilhelm Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanobodies are the products of an intriguing invention in the evolution of immunoglobulins. This invention can be traced back approximately 45 million years to the common ancestor of extant dromedaries, camels, llamas, and alpacas. Next to conventional heterotetrameric H2L2 antibodies, these camelids produce homodimeric nanobody‐based heavy chain antibodies, composed of shortened heavy chains that a lack the CH1 domain. Nanobodies against human target antigens are derived from immunized animals and/or synthetic nanobody libraries. As a robust, highly soluble, single immunoglobulin domain, a nanobody can easily be fused to another protein, for example to another nanobody and/or the hinge and constant domains of other immunoglobulins. Nanobody‐derived heavy chain antibodies hold promise as a new form of immunotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Heavy ChainsSingle-Domain AntibodiesAnimalsHumansCamelidaeImmunotherapyRecombinant Fusion Proteins

Stichwörter der Autor:innen

heavy‐chain antibodyimmunoglobulinimmunotherapeuticnanobody

Substanzen

Immunoglobulin Heavy ChainsRecombinant Fusion ProteinsSingle-Domain Antibodies

Autor:innen und Institutionen

  • Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Friedrich Koch-Nolte

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe
  • Wilhelm Sander-Stiftung
  • José Carreras Leukämie-Stiftung
  • Bundesministerium für Bildung und Forschung
  • Werner Otto Stiftung
  • Hamburger Krebsgesellschaft
  • European Cooperation in Science and Technology

Zitieren

APA

Koch-Nolte, F. (2024). Nanobody‐based heavy chain antibodies and chimeric antibodies. Immunological Reviews. https://doi.org/10.1111/imr.13385

Vancouver

Koch-Nolte F. Nanobody‐based heavy chain antibodies and chimeric antibodies. Immunological Reviews. 2024. doi:10.1111/imr.13385

BibTeX
@article{KochNolte2024,
  author = {Koch-Nolte, Friedrich},
  title = {Nanobody‐based heavy chain antibodies and chimeric antibodies},
  journal = {Immunological Reviews},
  year = {2024},
  doi = {10.1111/imr.13385}
}
Kostenlos starten →